A suitable crystal with dimensions 0.48 × 0.14 × 0.04 mm 3 was selected and mounted on a MITIGEN holder in Paratone oil on a Rigaku Oxford Diffraction XCalibur diffractometer. The crystal was kept at a steady T = 120.0 K during data collection. The structure was solved with the ShelXT solution program using dual methods, employing Olex2 as the graphical interface. The model was refined with ShelXL 2018/3 using full matrix least squares minimisation on F 2 . Three of the ligands were modelled as a disordered mixture of hmp and pic, as evidenced by a residual peak in a difference map which corresponded to the additional O site in the pic ligand. Each disorder was refined with a separate free variable. Specific occupancy values are given in the CIF; this explains the fractional values in the formula. Other than constructing an appropriate disorder model for the CH2 group the ring atoms of each hmp/pic disorder were not split as this was not justified by either the displacement ellipsoids or residual electron density peaks. Crystal Data. C78H87.09Cl2N12Ni7O30.45, Mr = 2161.75, triclinic, P-1 (No. The final wR2 was 0.1078 (all data) and R1 was 0.0465 (I≥2 (I)). CCDC 2286832. Powder XRD data of compound 1 (Figure ) were collected on a polycrystalline powder using a Bruker D8 ADVANCE in transmission mode fitted with a LynxEye detector using Cu radiation at 40 kV, 40 mA and a Johansson monochromator, 2 mm divergence slit and 2.5° Soller slits on the incident beam side. Bruker's DIFFRAC software was used to control the diffractometer. Diffraction data were measured from 2θ = 5° -40°; step size, 0.0101°.